Johns Hopkins University, Dept. of Biostatistics Working Papers

6-19-2013

TRIAL DESIGNS THAT SIMULTANEOUSLY
OPTIMIZE THE POPULATION ENROLLED
AND THE TREATMENT ALLOCATION
PROBABILITIES
Brandon S. Luber
Johns Hopkins School of Medicine, Department of Oncology, Division of Biostatistics and Bioinformatics, bsluber@jhu.edu

Michael Rosenblum
Johns Hopkins Bloomberg School of Health, Department of Biostatistics

Antoine Chambaz
Modal"X, Universite' Paris Quest

Suggested Citation
Luber, Brandon S.; Rosenblum, Michael; and Chambaz, Antoine, "TRIAL DESIGNS THAT SIMULTANEOUSLY OPTIMIZE THE
POPULATION ENROLLED AND THE TREATMENT ALLOCATION PROBABILITIES" ( June 2013). Johns Hopkins University,
Dept. of Biostatistics Working Papers. Working Paper 256.
http://biostats.bepress.com/jhubiostat/paper256

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors

Trial Designs that Simultaneously Optimize the
Population Enrolled and the Treatment Allocation
Probabilities
Brandon S. Luber ∗, Michael Rosenblum†, and Antoine Chambaz‡
June 18, 2013

Abstract
Standard randomized trials may have lower than desired power when the treatment
effect is only strong in certain subpopulations. This may occur, for example, in populations with varying disease severities or when subpopulations carry distinct biomarkers
and only those who are biomarker positive respond to treatment. To address such
situations, we develop a new trial design that combines two types of preplanned rules
for updating how the trial is conducted based on data accrued during the trial. The
aim is a design with greater overall power and that can better determine subpopulation
specific treatment effects, while maintaining strong control of the familywise Type I error rate. The first component of our design involves response-adaptive randomization,
in which the probability of being assigned to the treatment or control arm is updated
during the trial to target an optimal allocation. The second component of our design
involves enrichment, where the criteria for patient enrollment may be modified to help
learn which subpopulations benefit from the treatment. We do a simulation study to
compare the power of our design, which we call a response-adaptive enrichment design, to three simpler designs: a standard randomized trial design, a response-adaptive
design, and an enrichment design. Our simulation study compares these designs in
scenarios that arise from the problem of testing the effectiveness of a hypothetical new
antidepressant.
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1

Introduction

In 2006, the Critical Path Opportunities List was released by the U.S. Food and Drug Administration (FDA), outlining 76 projects aimed at improving the success rate of bringing
new medical discoveries from the lab to the patient. One set of projects involved improving
methods for the use of adaptive designs in clinical trials (Chow and Corey, 2011). The goals
of adaptive designs include designing a study that (1) is more efficient, (2) increases the
success rate of the study objective, or (3) yields a better understanding of the treatment’s
results (FDA, 2010). We propose a new adaptive design that combines features of an enrichment design and a response-adaptive design. To the best of our knowledge, this is the
first design combining these features. Our goal is to determine how these features interact,
in terms of power to detect treatment benefits in different subpopulations.
Enrichment designs allow pre-planned rules for changing the population enrolled, and
may be helpful when the results of a treatment may substantially vary in predefined subpopulations. An adaptive randomization, or response-adaptive design, uses the responses of
part participants to adjust the probabilities of treatment assignments for future participants.
This can potentially increase power through the adjustment of probabilities of treatment assignments in each subpopulation to target an optimal allocation ratio, such as the Neyman
allocation (defined below). Response-adaptive designs may be useful when it is believed
that a treatment or intervention not only shifts the mean of the outcomes distribution, but
also alters the variance of the outcomes. The approach may only be reasonable for a trial
with a short duration between enrollment and observation of the primary outcome, since the
randomization probability is dependent upon the observed outcomes of the previous participants (Chow and Chang, 2008). To take advantage of the benefits that adaptive designs
can potentially offer, rapid data collection and speedy application are required (Gallo et al.,
2006).
The motivation for combining enrichment and response-adaptive randomization into a
single design is the potential for synergy. This could arise, for example, if response-adaptive
randomization generates more relevant information not only for use in the final analysis,
but also for use in interim analyses. If better information is available at interim analyses,
this may lead to better interim decisions regarding which populations to continue enrolling
from and which to stop, i.e., this may improve the enrichment component of the design.
Our analysis aims to determine if such synergy is present for a particular response-adaptive
enrichment design, and if so to determine how useful such a design could be in practice.
According to (FDA, 2010), both response-adaptive and enrichment designs are “less
well understood, pose challenges in avoiding introduction of bias, and generally call for
2
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statistical adjustment to avoid increasing the Type I error rate.” In Section 3, with the
above considerations in mind, we aim to extend the theoretical framework of a two-stage
enrichment design of (Rosenblum and van der Laan, 2011) to incorporate response-adaptive
randomization, while maintaining strong control of the familywise Type I error rate, defined
as the probability of rejecting at least one true null hypothesis.
In addition to results for our response-adaptive enrichment design, we extend the results
of (Rosenblum and van der Laan, 2011) to trial designs with fixed randomization ratios that
are not 1:1, and that may even be different across subpopulations. In Section 4 we show a
power simulation that compares our response-adaptive enrichment design to the enrichment
design from (Rosenblum and van der Laan, 2011), a response-adaptive design, and a standard
fixed design. We consider settings where the variance of the outcome under assignment to
control is different than that under assignment to treatment, since it is under such scenarios
that adapting the randomization probabilities has the most potential to increase power. We
also explore how the different designs perform in terms of the average number of patients
assigned to the superior versus inferior treatment arm.
2

Related Work

Our motivation for considering response-adaptive enrichment designs is to improve power
and the ability to distinguish subpopulation treatment effects, compared to standard designs.
We base our design on the enrichment design of (Rosenblum and van der Laan, 2011),
and augment it with response-adaptive randomization for each subpopulation. They give
a method for constructing randomized trial designs that allow changes to the population
enrolled based on interim data using a prespecified decision rule, while maintaing strong
control of the asymptotic, familywise Type I error rate at a specified level α. They only
consider designs that have rules to potentially change which population is enrolled, and do
not modify other design parameters such as the total sample size or the randomization ratios.
However, they do conjecture that their general method may be extended to designs such as
the one here that also involve adapting the randomization probabilities; this is the open
problem we tackle.
According to (Karrison et al., 2003), although there has been substantial statistical literature in the area of response-adaptive designs, there has been little use of them in practice.
They point to several reasons why response-adaptive designs are not commonly used, including the logistical challenges of implementing an adaptive assignment scheme, and “the
potential for bias due to selection effects, ’drift’ in patient characteristics or risk factors
over time, and other sources”. There is also great debate as to the usefulness of response3
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adaptive designs. (Korn and Freidlin, 2011) found only a small benefit in using these designs
over standard fixed designs, although the context of their simulations was different from the
one here. These important limitations should be kept in mind when considering designs involving response-adaptive randomization. To be useful in practice, response-adaptive designs
should offer substantial benefits in order to outweigh these limitations.
Our proposed design allows for preplanned changes to the population enrolled, and is
potentially useful when it is thought there may be differing treatment effects across subpopulations. Such differences by subpopulation were observed, for example, in the study
from (Gunnarsdottir et al., 2010), whose aim was to investigate TOP2A gene copy number
changes as a means to identify groups of breast cancer patients who benefit from anthracycline treatment. In this trial, patients were randomly assigned to receive intravenous CMF
(cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin
and fluorouracil). Subgroup analyses supported that superiority of CEF over CMF may be
limited to patients with TOP2A mutations, whose tumors have TOP2A ratios below 0.8 or
above 2.0 (Gunnarsdottir et al., 2010). In another example, which we describe below, there
is suggestive evidence that the efficacy of certain antidepressants may depend on the initial
severity of depression (Kirsch et al., 2008).
3
3.1

Response-Adaptive Enrichment Design
Overview

There is suggestive evidence from the meta-analysis in (Kirsch et al., 2008) that certain
antidepressants may only be superior to a control, on average, for the population with severe
pre-treatment depression. We present a response-adaptive enrichment design motivated by
this work, where we consider planning a future trial of a new hypothetical antidepressant
treatment. Using (Kirsch et al., 2008) as a motivation, we will have a Hamilton Rating Scale
of Depression (HRSD) score recorded at baseline for each participant, along with his/her
corresponding HRSD score after the trial. Define each participant’s improvement to be the
difference between baseline HRSD score and HRSD score at end of follow-up. A negative
value of this difference means the participant got worse.
Define subpopulation 1 to be those with moderate pre-treatment depression at baseline,
and subpopulation 2 to be those with severe pre-treatment depression at baseline. Define the
total population to be the union of these disjoint subpopulations. We assume the proportions
of the total population that correspond to subpopulations 1 and 2 remain unchanged over
the trial duration.

4
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Define H02 to be the null hypothesis that the mean improvement corresponding to treatment is no more than that corresponding to control in subpopulation 2. In a similar manner,
define the null hypothesis H00 corresponding to the total population. For each null hypothesis, define the alternative hypothesis to be that the mean improvement under the new
anti-depressant drug is greater than under control. We focus on these null hypotheses, since
the meta-analysis of (Kirsch et al., 2008) suggests there will be a treatment benefit for the
total population, for only subpopulation 2, or for no population. It is an area of future
research to additionally consider the null hypothesis for subpopulation 1.
We now introduce our response-adaptive enrichment design, depicted in Figure 1. We first
present the overall idea, and then formally define the design in Section 3.2. The responseadaptive enrichment design consists of two main stages, separated by a decision step. Each
main stage has two parts. The total number of participants to be enrolled in the first and
second stages are pre-specified, and cannot be modified.
Stage 1.1 (first part of stage 1) Participants are drawn from the total population. Each
enrolled participant is randomly assigned to either the treatment arm or the control
arm with a 50% chance. Using a stratified block randomization, we can ensure that
approximately 50% of the participants in subpopulations 1 and 2 are assigned to each
arm.
Stage 1.2 (second part of stage 1) Participants are drawn from the total population.
Each enrolled participant is randomly assigned either to the treatment arm or to the
control arm with differing probabilities, determined by targeting the Neyman allocation
of treatment and control for each subpopulation separately.
The purpose of having two parts to stage 1 is to allow enough information to accrue about
differences in the outcome variances under treatment versus control in stage 1.1, in order
to adequately modify the randomization probabilities in stage 1.2. This also ensures that a
minimum number of participants are assigned to each arm.
At the conclusion of stage 1, when all stage 1 data is available for interim analysis,
(1)
(1)
(1)
we compute three z-statistics, T0 , T1 , T2 , which correspond to the total population,
subpopulation 1, and subpopulation 2, respectively. The (1) superscript is a reminder that
these statistics are computed at the end of stage 1. Each of these z-statistics represents the
standardized difference between the mean change in outcome under treatment and under
control. They are defined in Section 3.2.
Decision step We decide to keep enrolling from the total population during stage 2 if
5
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(1)

(1)

(1)

T1 > T2 or T1
during stage 2.

> 0.3. Otherwise, we decide to enroll only from subpopulation 2

In words, we continue to enroll from both subpopulations in stage 2 if we see either a
greater estimated, standardized treatment effect in subpopulation 1 than in subpopulation 2
(1)
(1)
(1)
(case T1 > T2 ) or a non-negligible positive signal for subpopulation 1 (case T1 > 0.3). If
we see neither of these, then we essentially give up on subpopulation 1, and enroll in stage 2
only from subpopulation 2. This only allows for potential enrichment of subpopulation 2.
Such a decision rule was used in (Rosenblum and van der Laan, 2011), where the threshold
0.3 was computed to be a value that gives a favorable power tradeoff in the simulation
scenarios we consider below.
Stage 2.1 (first part of stage 2) Each enrolled participant is randomly assigned to either
the treatment arm or the control arm with a 50% chance.
Stage 2.2 (second part of stage 2) Each enrolled participant is randomly assigned either to the treatment arm or the control arm with differing probabilities, determined,
again, by targeting the Neyman allocation of treatment and control for each subpopulation separately.
In both stages 1.2 and 2.2, the targeting is performed to reduce the asymptotic variance of
our final estimator (Chambaz and van der Laan, 2011). In estimating the Neyman allocation
in stage 2, we ignore all stage 1 data. This ensures that the data generated in stage 2 is
conditionally independent from the data generated in stage 1, given the enrollment decision
at the end of stage 1. This conditional independence is used in our proof of strong control of
the familywise Type I error rate for our design. We explore the impact of sharing information
between stages in determining the Neyman allocation in stage 2, in Section 4.4.
Hypothesis Test We compute a final test statistic, Tfinal , as a weighted combination of
(1)
T0 and the stage 2 statistic T (2) , defined below, that incorporates all stage two data.
If Tfinal > Φ−1 (0.95) then we reject H0s , where s = 0 if we enrolled from the total
population in stage 2 and s = 2 otherwise.

3.2

Formal Definition of Response-Adaptive Enrichment Design

We now formally define the statistics that will be used in the above decision rule and testing
procedure. For ease of comparability, we use the same notation as in (Rosenblum and van
der Laan, 2011).
6
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Enrollment Procedure of Response-Adaptive Enrichment Design
Stage 1.1

Stage 1.2

Enroll ω participants, using
1:1 randomization, from:

Enroll n1 − ω
participants targeting the Neyman allocation,
based on stage 1
data, from:

Decision step

(1)

Subpopulation 1 and
Subpopulation 2

(1)

Stage 2.1

Stage 2.2

Enroll ω participants, using
1:1 randomization, from:

Enroll n2 − ω
participants targeting the Neyman allocation,
based on stage 2
data, from:

If T1 > T2
(1)
or T1 > .3

Subpopulation 1 and
Subpopulation 2

Else,

Subpopulation 2

Figure 1: A flow chart of the proposed response-adaptive enrichment design,
where enrollment after the first ω patients targets the Neyman allocation for
each stage, and where enrollment for stage two is based on our pre-defined
decision rule.

Every participant m contributes the data (Im , Sm , Am , Ym ) where Im ∈ {1, 2} indicates in
which stage the participant entered, Sm ∈ {1, 2} indicates the participant’s subpopulation,
Am ∈ {0, 1} indicates whether the participant was assigned to the treatment arm (Am = 1)
or control arm (Am = 0), and Ym ∈ R is the outcome of interest.
For fixed M1 , M2 , τ that do not depend on sample size, define Q to be the class of
distributions Q on R such that supQ∈Q {EQ [|Y − µ(Q)|3 /σ 2 (Q)3/2 ]} ≤ M1 < ∞, and for each
s ∈ {1, 2}, a ∈ {0, 1} we have τ ≤ σ 2 (Q) ≤ M2 . These properties are used in our proofs
of strong control of the familywise Type I error rate, which rely on uniform, multivariate
central limit theorems.
Let µ(Q) and σ 2 (Q) denote the mean and variance of Q ∈ Q. For each s ∈ {1, 2},
a ∈ {0, 1}, let Qsa ∈ Q denote the (unknown) distribution of the outcome of interest
for subpopulation s under treatment arm assignment a. The probability φs of assignment
to the treatment arm that minimizes the asymptotic variance of the maximum likelihood
estimator of the mean treatment effect, the so-called Neyman allocation, is given by φs =
σ(Qs1 )/[σ(Qs1 ) + σ(Qs0 )] for each s ∈ {1, 2} (Rosenberger and Hu, 2004).
Let p1 and p2 denote the probabilities that a participant uniformly drawn from the total
population belongs to subpopulation 1 and subpopulation 2, respectively. We assume p1 and
p2 are known and fixed throughout the trial. Let n1 and n2 denote the pre-specified numbers
of participants in stage 1 and stage 2. These are chosen such that 0.05 ≤ n1 /(n1 +n2 ) ≤ 0.95.
In each stage where participants are enrolled from the total population (i.e., for stage 1,
7
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and possibly for stage 2, depending on the decision made after completion of stage 1), the
proportions of enrolled participants from subpopulations 1 and 2 are assumed to equal p1
and p2 , respectively; more precisely, we assume in this case that the set of participants with
Sm = 1 enrolled in stage i ∈ {1, 2} is a uniformly drawn random subset of p1 ni out of the ni
total sample size in that stage. We assume that for each participant m, conditioned on Im ,
Sm = s, Am = a, and all the data of previously enrolled participants, the outcome Ym is a
random draw from Qsa .
The two null hypotheses are defined as:
H02 : µ(Q21 ) − µ(Q20 ) ≤ 0 and H00 : p1 [µ(Q11 ) − µ(Q10 )] + p2 [µ(Q21 ) − µ(Q20 )] ≤ 0.
Stage 1.1 Enroll ω participants from the total population. Each participant is assigned to
the treatment arm or to the control arm with a 50% chance.
Stage 1.2 Compute σ̂ 2 (Q11 ), σ̂ 2 (Q10 ), σ̂ 2 (Q21 ), σ̂ 2 (Q20 ), the sample variances in the ω patients enrolled in stage 1.1, which are unbiased estimators of σ 2 (Q11 ), σ 2 (Q10 ), σ 2 (Q21 ),
σ 2 (Q20 ), respectively. This allows us to compute initial estimators φ̂1 and φ̂2 of the
Neyman allocations φ1 and φ2 .
Enroll n1 − ω participants from the total population. The estimators σ̂ 2 (Q11 ), σ̂ 2 (Q10 ),
σ̂ 2 (Q21 ), σ̂ 2 (Q20 ) are updated after each enrolled participant, with each update yielding updated estimators φ̂1 and φ̂2 . Participants from subpopulation 1 are randomly
assigned to the treatment arm with probability φ̂1 , the current estimator of φ1 , while
participants from subpopulation 2 are randomly assigned to the treatment arm with
probability φ̂2 , the current estimator of φ2 .
Decision step Define for each i ∈ {1, 2} and s ∈ {1, 2} the statistics
1/2



se(i)
= 
s


σ̂ 2 (Qs1 )
X

Am

m:Im =i,Sm =s



X


σ̂ 2 (Qs0 )

X

(1 − Am )

+

,

m:Im =i,Sm =s

Y m Am

 m:Im =i,Sm =s
X
Ts(i) = 
−

Am
m:Im =i,Sm =s

X
m:Im =i,Sm =s

X

Ym (1 − Am )




 /se(i)
s ,
(1 − Am ) 

(1)

m:Im =i,Sm =s
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(i)

se0

(i)

T0
(1)

=



=



(1)

(i)

(i)

p21 (se1 )2 + p22 (se2 )2
(i)

(i)

(i)

1/2

(i)

p1 se1 T1 + p2 se2 T2



,
(i)

/se0 .

(2)

(1)

The statistics se1 , se2 , and se0 should be thought of as estimators of the standard
(1)
(1)
(1)
errors of the numerators in the definitions of T1 , T2 , T0 , respectively.
Compute the above statistics at i = 1. We decide to keep enrolling from the total
(1)
(1)
(1)
population during stage 2 if T1 > T2 or T1 > 0.3. Otherwise, we decide to enroll
only from subpopulation 2 during stage 2.
Stage 2.1 Enroll ω participants from the selected population. Each participant is assigned
to the treatment arm or control arm with a 50% chance.
Stage 2.2 Compute the sample variances σ̂ 2 (Q21 ) and σ̂ 2 (Q20 ) based on the ω patients
enrolled in stage 2.1. If the selected population includes subpopulation 1, similarly
compute σ̂ 2 (Q11 ) and σ̂ 2 (Q10 ). This allows computing a new initial estimator φ̂2 of the
Neyman allocations φ2 , and if the selected population includes subpopulation 1, a new
initial estimator φ̂1 of the Neyman allocations φ1 .
Enroll n2 − ω participants from the selected population. The estimators σ̂ 2 (Q21 ),
σ̂ 2 (Q20 ), and possibly σ̂ 2 (Q11 ), σ̂ 2 (Q10 ) if the selected population includes subpopulation 1, are updated based on stage 2 data only, each update yielding updated estimators
φ̂1 and φ̂2 . Participants from subpopulation 2 are randomly assigned to the treatment
arm with probability φ̂2 . If the selected population includes subpopulation 1, then
stage 2.2 participants from subpopulation 1 are randomly assigned to the treatment
arm with probability φ̂1 .
(2)

Hypothesis Test Define T (2) = T0 if the selected population is the total population;
(2)
otherwise, set T (2) = T2 . The final test statistic is the weighted combination of the
test statistics from stages 1 and 2 given by

Tfinal =

n1
n1 + n2

1/2

(1)
T0


+

n2
n1 + n2

1/2

T (2) .

If Tfinal > Φ−1 (0.95) then we reject the null hypothesis corresponding to the selected
population enrolled from in stage 2, i.e. either H00 or H02 depending on whether the

9
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selected population is the total population or subpopulation 2, respectively; otherwise
we fail to reject any null hypothesis.
3.3

Control of Familywise Type I Error Rate for Response-Adaptive Enrichment Design
(1)

(1)

(1)

Consider the statistic T = (T0 , T1 , T2 , T (2) ), whose joint distribution we denote Pn with
n = n1 +n2 . Define the class of 4-tuples of distributions Q4 = {(Q11 , Q10 , Q21 , Q20 ): each Qsa ∈
Q}. As in (Rosenblum and van der Laan, 2011), we define strong control of the (asymptotic)
familywise Type I error rate at level α to be:
lim sup sup PQ,n (At least one true null hypothesis is rejected) ≤ α.

n1 ,n2 →∞ Q∈Q4

Consider the case where the variances Qsa are known. Then the true Neyman allocations φ1 , φ2 can be computed exactly. We prove in the Supplementary Material that if the
true Neyman allocations are used in place of estimated Neyman allocations throughout the
response-adaptive enrichment design, it strongly controls the familywise Type I error rate
at level 0.05. We conjecture that this result holds for the more realistic case of estimated
variances and estimated Neyman allocations. The plausibility of this conjecture is supported
by Theorem 2 from Section 4 of Chambaz and van der Laan (2011), which, roughly speaking,
states that in the limit as sample size goes to infinity, the statistics in the response-adaptive
design using estimated Neyman allocations behave as if the true Neyman allocations were
known and used from the start.
We conducted simulations, described in Section 4.6, comparing the performance of the
response-adaptive enrichment design (which uses estimated variances and estimated Neyman allocations) to the counterpart using known variances and true Neyman allocations, at
n = 488. The resulting power and Type I error were nearly identical in all scenarios we
considered. However, it remains an area of future work to prove strong control of the familywise Type I error rate for the response-adaptive enrichment design. The main difficulty
in showing this is handling the dependence induced by the response-adaptive component of
our design. Martingale arguments such as those in (Rosenberger and Lachin, 2002, Chapter
13) or (Chambaz and van der Laan, 2013) could potentially be used to show this. Instead of
investigating this issue, we focus our energy on simulations that investigate the finite sample
performance of our design. However, we note that in all our simulations (except those in
Section 4.6), variances are estimated rather than assumed known.

10
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4

4.1

Comparison of Designs in Terms of Power and Number Assigned to Superior
Study Arm
Definition of Designs

Our simulations are motivated by (Kirsch et al., 2008). We compare our response-adaptive
enrichment design to a standard fixed design, a response-adaptive design (with no enrichment), and an enrichment design (with no response-adaptive randomization). All designs
have the same total sample size n = n1 + n2 = 488.
The standard fixed design enrolls from the total population and uses 1:1 randomization to
treatment and control throughout the trial. The response-adaptive design uses the responseadaptive procedure as described in Sections 3.1 and 3.2, but does not include the enrichment
design component; enrollment is from the total population in both stages. For these designs,
the null hypothesis H00 is rejected if Tfinal > Φ−1 (0.95) at the end of the trial. The enrichment
design is the same as the response-adaptive enrichment design defined in Sections 3.1 and
3.2, except randomization is 1:1 throughout the trial.
We augment all of the above designs, including the response-adaptive enrichment design,
to allow additional testing of H02 whenever H00 is rejected. This is based on the idea
of a fixed sequence testing procedure as in (Maurer et al., 1995). Whenever one of the
above designs rejects H00 , the following test is carried out: if the z-statistic combining all
the subpopulation 2 data from both stages exceeds a certain threshold, reject H02 . This
threshold is set to be Φ−1 (0.95) for the standard fixed design and the response-adaptive
design. It follows from the results of (Maurer et al., 1995) that strong control of familywise
Type I error rate is maintained at level 0.05 for the standard fixed design and the responseadaptive design. The threshold is slightly increased to Φ−1 (0.95) + 0.055 for the enrichment
and response-adaptive enrichment designs. It is shown in the Supplemental Material of
(Rosenblum and van der Laan, 2011) that this augmented procedure controls the asymptotic,
worst-case familywise Type I error at 0.05 for the enrichment design. We prove the same
for the response-adaptive enrichment design in the Supplementary Material, in the case in
which the variances are assumed known.
4.2

Definition of Scenarios

We compare the power of our response-adaptive enrichment design to the other designs under
six scenarios, numbered 1A, 1B, 1C, 2A, 2B, 2C. Each of the six scenarios is defined exactly
as in (Rosenblum and van der Laan, 2011) for ease of comparison. In particular, Q11 , Q10 ,
Q21 and Q20 are Gaussian distributions.
11
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In scenarios 1A, 1B, 1C, we set p1 = p2 = 1/2 and n1 = n2 = 244. In scenarios 2A,
2B, 2C, we set p1 = 0.75, p2 = 0.25 and n1 = (0.3)(488) = 146, n2 = (0.7)(488) = 342.
Each of ‘A’, ‘B’, and ‘C’ corresponds to a different setting of the outcome means µ(Qsa )
under treatment and control for each subpopulation. These are defined next, motivated by
scenarios observed in (Kirsch et al., 2008).
In the meta-analysis of (Kirsch et al., 2008), the average change in HRSD points, comparing each participant’s final score to baseline score, was 7.8 in the placebo arm for those
with moderate depression; it was 6.6 HRSD points in the placebo arm for those with severe depression. The point estimate for the treatment effect comparing change in HRSD
between treatment and placebo was approximately 0 HRSD points for those with moderate
depression (though this was based on a single study), 1.8 points in those with severe initial
depression, and 3.0 points for those with very severe initial depression.
For scenarios 1A and 1B, we set the data generating distributions to mimic what was
seen in (Kirsch et al., 2008): zero treatment effect for those with moderate pre-treatment
depression (µ(Q10 ) = µ(Q11 ) = 7.8) and a positive treatment effect for those with severe
pre-treatment depression. We set this positive treatment effect to be 1.8 points in scenario
1A (µ(Q20 ) = 7.8, µ(Q21 ) = 9.6), and 3.0 points in scenario 1B (µ(Q20 ) = 6.6, µ(Q21 ) = 9.6).
In scenario 1C, the data generating distributions are set to reflect a 1.8 point, positive
treatment effect for both those with moderate pre-treatment depression and those with
severe pre-treatment depression (µ(Q10 ) = µ(Q20 ) = 7.8, µ(Q11 ) = µ(Q21 ) = 9.6). For
scenarios 2A, 2B, and 2C, we assume the same values for the means µ(Qsa ) as in 1A, 1B,
and 1C, respectively.
The results of (Kirsch et al., 2008) include estimates of the total population standard
deviation being approximately 8.0 HRSD points, both under treatment and under control.
In our data generating distributions, we set the variance under treatment to be the same
for each subpopulation; similarly we will set the variance under control (which can differ
from that under treatment) to be the same for each subpopulation. We define the ratio
of outcome standard deviations under treatment and control in each subpopulation to be
r = σ(Q11 )/σ(Q10 ) = σ(Q21 )/σ(Q20 ). Below, we set r to various values, and examine the
impact on the different designs. At r = 1, we have equal standard deviations under treatment
and under control; in this case 1:1 randomization is the optimal Neyman allocation, so we
do not expect any benefit of response-adaptive randomization. At values of r farther from 1,
we expect more benefit from the response-adaptive randomization on power. Our goal is to
see how the possible benefits of the response-adaptive component interact with enrichment.
So as to hone in on the effect of the response-adaptive component in our simulations, we

12
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construct our data generating distributions so that the power of the standard fixed design in
each scenario is unchanged as we vary the ratio r. To achieve this, it suffices that the noncentrality parameters for the z-statistics defined in Section 3.2 be invariant to r under the
standard fixed design, which occurs if σ 2 (Qs0 ) + σ 2 (Qs1 ) is a constant; we set this constant
to be 8 HRSD points, so that at r = 1 the variances equal those derived from (Kirsch et
al., 2008). This leads us to set, for each r > 0 and each s ∈ {1, 2}, the subpopulation
p
standard deviation σ(Qs0 ) = 8 2/(1 + r2 ) and σ(Qs1 ) = rσ(Qs0 ). Under this definition,
changing the value of r affects neither the power of the standard fixed design nor the power of
the enrichment design, but does affect the power of the designs involving response-adaptive
randomizaiton.
We ran simulations for each r ∈ {1, 1.5, 2, 2.5}. Table 1 shows the standard deviations
under treatment and control for these values of r. In all six of our scenarios, the total sample
size for the trial remains the same, at n = 488 participants. This sample size was chosen
such so that the power of the standard, fixed design to reject H00 in scenarios 1C and 2C
is 80%. For the response-adaptive enrichment design, we set ω = 50. For each scenario,
100,000 simulated trials were run under each design. The R code used for the simulations is
included in the Supplementary Material.
Table 1: Standard Deviation Values for r ∈ {1, 1.5, 2, 2.5}
r σ(Qs1 )
1
8
1.5 9.414
2 10.119
2.5 10.505

4.3

σ(Qs0 )
8
6.276
5.060
4.202

Summary of Simulation Results

Define the overall power of a design in a given scenario to be the probability of rejecting at
least one false null hypothesis. We next summarize the power of different designs under the
scenarios defined above; complete details are then given in Section 4.4. All power comparisons
are given as absolute differences, and values are rounded to the nearest percent.
Across all the values of r we explored, under each scenario, the response-adaptive enrichment design has at least as great overall power as any of the other three designs. When
r = 1, across scenarios 1A, 1B, 2A, and 2B, each design with enrichment has 14 - 42% more
overall power compared to the corresponding design without enrichment.
13
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Recall that the power of the fixed design and the enrichment design do not change with
r. As r is increased from 1 to 2.5, the response-adaptive design gains up to 7% more overall
power and the response-adaptive enrichment design gains up to 6% more power. Over all
scenarios, the gains in power comparing the response-adaptive design to the fixed design
were similar to the power gains comparing the response-adaptive enrichment design to the
enrichment design. Though there were small differences in the magnitudes of these gains,
with the most prominent being the comparison of r = 2.5 to r = 1 in scenarios 1A and 2A,
there does not appear to be a strong synergistic effect across all scenarios of response-adaptive
randomization and enrichment.
In Section 4.5, we examine the impact of enrichment and response-adaptive randomization on the expected number Nsup of participants assigned to the superior study arm.
Enrichment always improves or leaves unchanged Nsup compared to the analogous design
without enrichment. In contrast, response-adaptive randomization, which was tailored to
maximize power through the Neyman allocation, can increase or decrease Nsup , compared
to the analogous design using 1:1 randomization. In cases where response-adaptive randomization decreases Nsup compared to the fixed design, this was partially mitigated by adding
enrichment to the design.
4.4

Detailed Simulation Results: Power Comparison

Figures 2, 3, 4, 5 show, for each scenario, side-by-side bar plots of the proportion of simulated
trial in which each null hypothesis is rejected, when r = 1, 1.5, 2, 2.5. In each of the six
scenarios, the first bar is for the fixed design, the second bar is for the response-adaptive
design, the third bar is for the enrichment design, and the fourth bar is for the responseadaptive enrichment design. The height of each bar represents overall power, and this is
decomposed into the proportion of simulated trials in which only H02 is rejected, only H00
is rejected, and both are rejected.
At r = 1 (Figure 2), the standard deviations under treatment and control are equal.
This implies that the Neyman allocations for subpopulations 1 and 2, φ1 and φ2 , both equal
1/2. The response-adaptive design behaves almost identically as the fixed design, and the
response-adaptive enrichment design behaves almost identically as the enrichment design.
Therefore, at r = 1, we only summarize the differences between the enrichment design and
the fixed design, which were also given in Section 4 of (Rosenblum and van der Laan, 2011).
In scenarios 1A and 1B, the true treatment effect is zero for subpopulation 1 and positive
(beneficial) for subpopulation 2. In scenario 1A, the enrichment design has 14% more overall
power than the fixed design. In scenario 1B, the enrichment design has 21% more overall
14
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power than the fixed design. In scenario 1C, where the true treatment effect is positive for
both subpopulations, all designs have 80% overall power. In scenario 2A, the enrichment
design has 23% more overall power than the fixed design. In scenario 2B, the enrichment
design has 42% more overall power than the fixed design. In scenario 2C, the overall power
is identical to scenario 1C.
At r = 1.5 (Figure 3), the standard deviation σ(Qsa ) under assignment to the treatment
arm (a = 1) is 1.5 times that under assignment to control (a = 0). In all scenarios, the
absolute difference in overall power between the response-adaptive design and fixed design
was 1%. The same holds when comparing the response-adaptive enrichment design and
enrichment design.
At r = 2 (Figure 4), the standard deviation σ(Qsa ) under assignment to the treatment
arm is twice that under assignment to control. In scenarios 1A, 1B, and 1C, the responseadaptive design and the response-adaptive enrichment design have 2-3% more overall power
than the fixed design and the enrichment design, respectively. In scenarios 2A and 2B, there
is a gain of 1-2% in overall power comparing the response-adaptive design to the fixed design
and a gain of 2% comparing the response-adaptive enrichment design to the enrichment
design. In scenario 2C, the overall power is similar to scenario 1C.
At r = 2.5 (Figure 5), the standard deviation σ(Qsa ) under assignment to the treatment
arm is 2.5 times that under assignment to control. In scenario 1A the response-adaptive
design has 4% more overall power than the fixed design and the response-adaptive enrichment
design has 6% more overall power than the enrichment design. In scenario 1B, the responseadaptive design has 7% more overall power than the fixed design and the response-adaptive
enrichment design has 6% more overall power than the enrichment design. In scenario 1C,
each design involving response-adaptive randomization has 6% more overall power than the
corresponding design without this. In scenario 2A, the response-adaptive design has 2%
more overall power than the fixed design and the response-adaptive enrichment design has
5% more overall power than the enrichment design. In scenario 2B, the response-adaptive
design has 3% more overall power than the fixed design and the response-adaptive enrichment
design has 4% more overall power than the enrichment design. The overall power in scenario
2C is similar scenario 1C.
We explored the impact of using both stage 1 and stage 2 data to estimate the Neyman
allocations during stage 2.2. The power and Type I error were nearly identical to the results
above (in which only stage 2 data is used in stage 2.2 to estimate Neyman allocations).
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r = 1: Probabilities of Rejecting Null Hypotheses: H00, H02, or Both H00 and H02, Comparing the Fixed
Design, Response−Adaptive Design, Enrichment Design, and the Response−Adaptive Enrichment Design
Scenario 1A

Probability of Rejection

1

.8

Scenario 1B

Scenario 1C

Scenario 2A

Scenario 2B

Scenario 2C

Null Hypothesis:
Reject H00 and H02
Reject H00
Reject H02

.6

.4

.2

0
F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

Trial Design

Figure 2: Power simulation with standard deviation ratio r = 1. Across
the six scenarios, we compare the fixed design, abbreviated F, the responseadaptive design, abbreviated RA, the enrichment design, abbreviated E, and
the response-adaptive enrichment design, abbreviated RAE.

r = 1.5: Probabilities of Rejecting Null Hypotheses: H00, H02, or Both H00 and H02, Comparing the Fixed
Design, Response−Adaptive Design, Enrichment Design, and the Response−Adaptive Enrichment Design
Scenario 1A

Probability of Rejection

1

.8

Scenario 1B

Scenario 1C

Scenario 2A

Scenario 2B

Scenario 2C

Null Hypothesis:
Reject H00 and H02
Reject H00
Reject H02

.6

.4

.2

0
F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

Trial Design

Figure 3: Power simulation with standard deviation ratio, r, set to 1.5.
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r = 2: Probabilities of Rejecting Null Hypotheses: H00, H02, or Both H00 and H02, Comparing the Fixed
Design, Response−Adaptive Design, Enrichment Design, and the Response−Adaptive Enrichment Design
Scenario 1A

Probability of Rejection

1

.8

Scenario 1B

Scenario 1C

Scenario 2A

Scenario 2B

Scenario 2C

Null Hypothesis:
Reject H00 and H02
Reject H00
Reject H02

.6

.4

.2

0
F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

Trial Design

Figure 4: Power simulation with standard deviation ratio, r, set to 2.

r = 2.5: Probabilities of Rejecting Null Hypotheses: H00, H02, or Both H00 and H02, Comparing the Fixed
Design, Response−Adaptive Design, Enrichment Design, and the Response−Adaptive Enrichment Design
Scenario 1A

Probability of Rejection

1

.8

Scenario 1B

Scenario 1C

Scenario 2A

Scenario 2B

Scenario 2C

Null Hypothesis:
Reject H00 and H02
Reject H00
Reject H02

.6

.4

.2

0
F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

F RA E RAE

Trial Design

Figure 5: Power simulation with standard deviation ratio, r, set to 2.5.

17

Hosted by The Berkeley Electronic Press

4.5

Detailed Simulation Results: Assignment to Superior versus Inferior Study
Arm

Our response-adaptive enrichment design targets the Neyman allocation, with the goal of
maximizing power. Response-adaptive randomization also impacts patient exposure to the
inferior versus superior study arm, as described by (Rosenberger and Hu, 2004).
We compare the different designs in each scenario, in terms of the expected number of
participants assigned to a superior arm, i.e., an arm for which the mean outcome is strictly
greater than under assignment to control for that participant’s subpopulation. Because for
all scenarios and subpopulations s, we have µ(Qs1 ) ≥ µ(Qs0 ), no participant assigned to
control is ever assigned to a superior arm. The expected number of participants assigned to
a superior arm, which we denote by Nsup , is equivalent to the expected number of participants
who receive a better treatment than if all participants had been assigned to control.
The top of Table 2 gives Nsup for the different designs, for each r ∈ {1, 1.5, 2, 2.5} and each
scenario. The value of Nsup is substantially greater in the enrichment design compared to the
fixed design in scenarios 1A, 1B, 2A, 2B; this is because only one subpopulation benefits in
these scenarios, and the enrichment design enrolls more of these participants (who are then
assigned to the superior arm with probability 50%) with non-negligible probability. The
values of Nsup are equal in the enrichment and fixed designs in scenarios 1C and 2C, since
both subpopulations benefit from treatment in these scenarios.
The value of Nsup is greater in the response-adaptive design compared to the fixed design
for all scenarios when r > 1, since the response-adaptive design generally assigns more
participants to treatment in these cases.
Under scenarios 2A and 2B there is a synergistic effect of enrichment and responseadaptive components, in terms of the difference in Nsup due to enrichment and due to
response-adaptive randomization. This is most pronounced at r = 2.5, where the difference in Nsup comparing the response-adaptive enrichment design to the enrichment design
is nearly double the difference in Nsup comparing the response-adaptive design to the fixed
design.
We also considered simulations where for each subpopulation, σ 2 (Qs1 ) < σ 2 (Qs0 ). The
bottom of Table 2 compares the different designs, for each r ∈ {1, 1/1.5, 1/2, 1/2.5} and each
scenario. Similar results as above hold comparing the enrichment design to the fixed design in
terms of Nsup . However, adding response-adaptive randomization now decreases the number
of participants receiving superior treatment, because the Neyman allocation assigns more
participants to control. This decrease is partially mitigated by combining enrichment (which
always increases or does not change Nsup ) with response-adaptive randomization.
18
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Table 2: Exposure to Superior Study Arm Assignment, r ∈ {1, 1.5, 2, 2.5}
(top) and r ∈ {1, 1/1.5, 1/2, 1/2.5} (bottom)

1a
Fixed
122
Response-Adaptive
123
Enrichment
158
Response-Adaptive Enrichment 158

1a
Fixed
122
Response-Adaptive
159
Enrichment
157
Response-Adaptive Enrichment 200

1a
Fixed
122
Response-Adaptive
123
Enrichment
158
Response-Adaptive Enrichment 158

1b
122
123
159
160

r=1
1c
2a 2b
2c
244 61 61 244
244 61 61 244
244 129 135 244
244 129 134 244

1b
122
159
159
203

r=2
1c
2a 2b
2c
244 61 61 244
317 80 80 317
244 129 134 244
309 165 172 309

1b
122
123
159
160

r=1
1c
2a 2b
2c
244 61 61 244
244 61 61 244
244 129 135 244
244 129 134 244

r=
1a 1b 1c
Fixed
122 122 244
Response-Adaptive
86 86 171
Enrichment
157 159 244
Response-Adaptive Enrichment 116 118 179

1b
122
145
159
185

r=
1c
244
288
244
283

1.5
2a 2b 2c
61 61 244
72 72 288
129 134 244
151 157 283

1b
122
170
159
215

r=
1c
244
338
244
328

2.5
2a 2b 2c
61 61 244
85 85 338
129 135 244
176 183 327

1a
122
100
158
133

1b
122
100
159
134

r = 1⁄1.5
1c
2a 2b 2c
244 61 61 244
200 50 50 200
244 129 134 244
205 107 112 205

1a
122
75
158
105

r = 1⁄2.5
1b 1c
2a 2b 2c
122 244 61 61 244
75 150 37 37 150
159 244 129 135 244
106 161 83 87 160

1a
122
145
158
184

1a
122
170
157
213

1

⁄2

2a 2b
2c
61 61 244
42 42 171
129 135 244
93 97 179

The table provides the expected number of patients (rounded to the nearest integer)
assigned to a superior study arm out of 488 total patients.

19

Hosted by The Berkeley Electronic Press

4.6

Response-Adaptive Enrichment Design using True Neyman Allocations

We consider the case where the true Neyman allocations are used in the response-adaptive
enrichment design. We conducted 100,000 simulations at n = 488 and compared the performance to the response-adaptive enrichment design with estimated variances. Across all
scenarios, 1A-2C, and for each value r ∈ {1, 1.5, 2, 2.5}, the overall power was nearly identical between the two designs. The largest difference in overall power between the two designs
was 0.5%, under scenario 2B, at r = 2.
5

Type I Error Analysis

We ran simulations where we computed the familywise Type I error rate for the four designs
involved in the power analysis of Section 4, using 500,000 simulations per design per scenario.
We considered sample sizes n ∈ {244, 488}.
We first used Gaussian distributions Q11 , Q10 , Q21 , Q20 , all with zero mean. Across all
six scenarios above, 1A, 1B, 1C, 2A, 2B, 2C, the largest familywise Type I error for the fixed
design was 0.053, for the response-adaptive design was 0.052, for the enrichment design was
0.053, and for the response-adaptive enrichment design was 0.053.
We also considered heavy tailed and skewed data generating distributions. To investigate
the case of heavy tailed distributions, we set Q11 , Q10 , Q21 , Q20 to be identical, centered lognormal distributions, which is the distribution of exp(tZ) − exp(t2 /2), where Z is standard
normal; we considered each t ∈ {0.01, 0.1, 1, 2, 4}. To investigate the case of skewed distributions, we set Q11 , Q10 , Q21 , Q20 to be identical, centered negative binomial distributions
with added Gaussian noise, i.e., the distribution of Y − E(Y ) + 0.01Z, where Z is standard
normal and Y is a negative binomial distribution with parameters c ∈ {0.01, 0.1, 1, 2, 4} and
p = c/(c + 1).
Under the log-normal distributions, the familywise Type I error for the response-adaptive
enrichment design was always less than for the standard fixed design, except under a few
scenarios that the fixed design had type I error of zero. When t ∈ {0.01, 0.1}, for all
r ∈ {1, 1.5, 2, 2.5}, the standard fixed design had type I error of zero, and under these
scenarios, the largest familywise Type I error for the response-adaptive enrichment design
was 0.054. Under the negative binomial simulations, the familywise Type I error for the
response-adaptive enrichment design was always less than for the standard fixed design.
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6

Discussion

In our simulated scenarios, relatively large differences in the variances under treatment and
control are needed before a substantial power improvement (e.g. more than 5%) occurs
for the response-adaptive design and response-adaptive enrichment design, compared to the
standard fixed design and enrichment-only design, respectively. Due to this negative finding,
the situations in which such designs using response-adaptive randomization will have a large
impact on power may be limited. However, it was not known before our simulation study
whether there would be a synergistic effect on power of combining response-adaptive randomization and enrichment; a contribution of our work has been to explore this possibility.
We did observe a synergistic relationship between enrichment and response-adaptive randomization, not in power, but in terms of the number of participants assigned to the superior
study arm.
An open research question is to explore alternative adaptive randomization allocations
and determine after what proportion of enrolled participants one should schedule an interim
analysis, to optimize power and Nsup . A related issue is to determine how the ratios ω/n1
and ω/n2 affect the overall power estimates.
(Berry, 2010) argues that the advantage of response-adaptive designs is greater for
comparisons of more than two treatment arms. It is an area of future work to consider
response-adaptive enrichment designs for more than two treatment arms.
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